4//SEC Filing
Gano Kyle 4
Accession 0001567160-25-000008
CIK 0000914475other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 8:18 PM ET
Size
9.0 KB
Accession
0001567160-25-000008
Insider Transaction Report
Form 4
Gano Kyle
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-11-01−613→ 1,842 total→ Common Stock (613 underlying) - Exercise/Conversion
Common Stock
2025-11-01+613→ 140,720 total - Sale
Common Stock
2025-11-04$141.97/sh−300$42,591→ 140,407 total
Footnotes (4)
- [F1]Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F4]This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001567160
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 8:18 PM ET
- Size
- 9.0 KB